GSK’s Belimumab shows significant improvement in renal function in the largest Lupus Nephritis (LN) clinical study
In the most extensive study to date, GSK’s Belimumab (alongside Standard therapy) vs. placebo showed a significant improvement in LN renal response, such as renal filtration and urine protein creatinine. Moreover, Belimumab also demonstrated a favorable safety profile. The results were presented at the 2020 EULAR e-congress.